

**ASCENDIS HEALTH LIMITED**

(Incorporated in the Republic of South Africa)

(Registration number 2008/005856/06)

ISIN: ZAE000185005 JSE share code: ASC

("Ascendis" or "the Company")

**COMPLEMENTARY MEDICINES ("CMS") REGULATIONS EFFECTS ON  
ASCENDIS - CORRECTION**

In response to the Business Day article published on 10 June 2014, Ascendis hereby releases this corrective announcement which serves to clarify the statement pertaining to the portion of Ascendis' turnover affected by the new CMS regulations.

It should be duly noted that Ascendis' Consumer Brands Division represents approximately 40% of the Company's [annualised] turnover with Solal representing approximately 8% of Ascendis' annualised turnover. Up to a maximum of 20% of Solal's sales are potentially impacted by the CMS regulations which therefore amounts to 1,6% of Ascendis' annualised turnover being potentially impacted by the regulations and not the 9% as reported within the article.

Ascendis continues to perform well with robust organic growth, as previously reported within the interim results announcement released on 3 March 2014.

11 June 2014

Johannesburg

Sponsor

Investec Corporate Finance

Financial Advisor

Coast2Coast Investments